Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
872 7 |
Ultima descărcare din IBN: 2023-09-25 20:44 |
Căutarea după subiecte similare conform CZU |
616.72-002.772-07-085 (1) |
Patologia organelor de locomoţie. Sistemul osos şi locomotor (472) |
SM ISO690:2012 CRACEA (DRUŞCA), Angela, FOCA, Silvia-Gabriela, REVENCO, Ninel. Eficienţa clinică şi paraclinică a tratamentului cu tocilizumab la pacienţii cu artrită juvenilă idiopatică. In: Buletin de Perinatologie, 2017, nr. 1(73), pp. 9-12. ISSN 1810-5289. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletin de Perinatologie | ||||||
Numărul 1(73) / 2017 / ISSN 1810-5289 | ||||||
|
||||||
CZU: 616.72-002.772-07-085 | ||||||
Pag. 9-12 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Juvenile idiopathic arthritis (JIA) as defined ILAR (Durban, 1997; Edmonton, 2001), is a persistent arthritis which begins before the age of 16 years and with duration 6 weeks without being able to determine a definite cause of disease. In this study we include 13 children with JIA who administrated Tocilizumab every 2 weeks. We appreciate the number of painful joints, the number of swollen joints, the global evaluation of disease by the doctor and by the patient and Childhood Health Assessment Questionnaire (CHAQ). Also, we determine paraclinical indices: general blood analyzes, C-reactive protein. The results of the study show that during the treatment with Tocilizumab at the children with systemic form of juvenile idiopathic arthritis decrease the number of painful and swollen joints, the global evaluation of disease by the doctor and by the patient and Childhood Health Assessment Questionnaire (CHAQ). Also, we determine that the indices of acute phase of inflammation, the sedimentation rate of the erythrocyte and C-reactive protein decrease during the treatment with Tocilizumab. |
||||||
Cuvinte-cheie juvenile idiopathic arthritis (JIA), number of painful joints, number of swollen joints, the global evaluation of disease by the patient, the sedimentation rate of the erythrocyte, C-reactive protein, Tocilizumab, the global evaluation of disease by the doctor |
||||||
|